# Glecirasib

Source: https://onco.cc/drugs/glecirasib/  
OnCo record `glecirasib` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Glecirasib is Jacobio's KRAS G12C inhibitor, approved in China in 2024 for previously treated non-small cell lung cancer with that mutation, and in a phase 3 trial against docetaxel.

## Summary

Jacobio Pharma developed glecirasib (JAB-21822) and partnered it with Allist Pharmaceuticals for China. The NMPA approved it in 2024 for KRAS G12C-mutant non-small cell lung cancer after at least one prior systemic therapy, on a single-arm phase 2 trial with a response rate in the range of the approved Western inhibitors and a low rate of gastrointestinal side effects. A randomised phase 3 trial against docetaxel and combination studies with a SHP2 inhibitor are registered.

## Fields

- Kind: Treatment
- Status: approved
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Code: JAB-21822
- Modality: Oral covalent KRAS G12C inhibitor
- Mechanism: Binds the mutant cysteine of KRAS G12C and locks the protein in its inactive state, the same mechanism as sotorasib and adagrasib.
- Approvals: CN 2024: KRAS G12C-mutant advanced non-small cell lung cancer after prior systemic therapy

## Sources

- ClinicalTrials.gov: trials of Glecirasib: https://clinicaltrials.gov/search?intr=JAB-21822

## Connected records

- cancers: [KRAS G12C-mutant colorectal cancer](https://onco.cc/cancers/kras-g12c-colorectal/), [KRAS G12C-mutant non-small-cell lung cancer](https://onco.cc/cancers/kras-g12c-nsclc/), [KRAS G12C-mutant pancreatic ductal adenocarcinoma](https://onco.cc/cancers/kras-g12c-pdac/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- technologies: [KRAS & RAS inhibitors](https://onco.cc/technologies/kras-inhibitors/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- targets: [KRAS](https://onco.cc/targets/kras/), [SHP2 (PTPN11)](https://onco.cc/targets/shp2/)
- companies: [Jacobio Pharmaceuticals](https://onco.cc/companies/jacobio-pharmaceuticals/)
- trials: [A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib](https://onco.cc/trials/nct07164170/), [A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.](https://onco.cc/trials/nct06008288/), [A Study of BL-B01D1 Combined With Glecirasib in Patients With KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer](https://onco.cc/trials/nct07827261/), [A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China](https://onco.cc/trials/nct05009329/), [A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1](https://onco.cc/trials/nct05276726/), [A Trial of HRS-7058 in Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment](https://onco.cc/trials/nct07601048/), [JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation](https://onco.cc/trials/nct06416410/), [JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation](https://onco.cc/trials/nct05194995/), [Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation](https://onco.cc/trials/nct05288205/)

---
JSON: https://onco.cc/api/v1/entities/glecirasib.json